INDEX

VOLUME 26 1971

A

Adams, John G.—Research and Development of a New Drug. Jan., p. 9.

Administration and Enforcement

Analysis of the Application of the Salvaging Provision of the Food, Drug, and Cosmetic Act of 1938 (An). June, p. 240.

—And Where Has the Old Food and Drug Administration Gone? Oct., p. 539.

Court of Food and Drug Appeals (A). June, p. 279.

Drug Listing Law Takes Shape. Sept., p. 435.

Duty to Inform (The): The Responsibility to Comply. Mar., p. 102.

Food and Drug Administration Regulations v. Drug Manufacturers' Hearing Rights: An Analysis. May, p. 224.

Formulation of Mandatory Food Standards (The). Sept., p. 376.

Importance of Uniformity Among State Food and Drug Laws (The). Mar., p. 96.

Legal Procedures and Responsibilities Under the Federal Food, Drug, and Cosmetic Act. Aug., p. 334.

Problems Relating to Enforcement of Food and Milk Laws and Regulations: Industry Viewpoint. July, p. 288.

Regulating in the Public Interest. Nov., p. 593.

Reply to Professor Hamilton's Comments and Recommendations for Procedural Reform (A). Dec., p. 639.

Rulemaking on a Record. Dec., p. 627.

Some Aberrations in Administrative Law. June, p. 261.

Advertising, control of

Consumer Protection: Advertising —The FTC Response. Dec., p. 609.

Control of Television Advertising in Great Britain. Aug., p. 328.

Drug Abuse, Drug Culture, Drug Advertising. Oct., p. 482.

Drug Advertising and Drug Abuse —The Role of the FTC. Oct., p. 487.

Industry Reaction to Prescription Drug Advertising Regulations and Their Enforcement. Oct., p. 534.

Regulating in the Public Interest. Nov., p. 593.

What Is "Unfair Advertising"? Dec., p. 658.

After Panalba, Whither? Apr., p. 186.

Analysis of the Application of the Salvaging Provision of the Food, Drug, and Cosmetic Act of 1938 (An). June, p. 240.

Analysis and Testing

Challenge of Progress in Food (The). Aug., p. 365.

Investigational Clinical Studies. Jan., p. 4.

Microbiology in FDA—New Horizons. Jan., p. 28.

Poison Prevention Packaging Act (The). Sept., p. 447.

Progress Report on Clinical Guidelines. Feb., p. 78.

XUM

Research and Development of a New Drug. Jan., p. 9.

—And Where Has the Old Food and Drug Administration Gone? Oct., p. 539.

Armstrong, Donald B., Jr.—What Do We Mean by "New Products?" Nov., p. 558.

Austern, H. Thomas

Formulation of Mandatory Food Standards (The). Sept., p. 376.

Some Aberrations in Administrative Law. June, p. 261.

What Is "Unfair Advertising"? Dec., p. 658.

B

Barmak, Mark E.—A Potpourri of Trademark and Labeling Regulations for Drug Products. May, p. 208.

Baxter, Charles E.—Nutritional Labeling: An Analysis. Feb., p. 82.

Bibliography

International Aspects of Food and Drug Legislation. July, p. 303.

Bigwood, E. J.—The Cultural and Social Foundations of Food Laws. (A. Gérard, co-author) July, p. 296.

Brown, Gordon R.—Corporate Counsel's Responsibility in the Age of Consumerism. Apr., p. 154.

Burditt, George M.—The Importance of Uniformity Among State Food and Drug Laws. Mar., p. 96.

Byerley, Walter E.—Special Problems with Dietary Foods. Nov., p. 584.

C

Challenge of Progress in Food (The). Aug., p. 365.

Cheng, An-Shih—Drug Abuse, Drug Culture, Drug Advertising. Oct., p. 482.

Clausi, A. S.—The Trouble with New Products. Nov., p. 569.

Cody, William F.

Creating a Legally Viable Food Product. Nov., p. 575.

Food Standards and the White House Conference on Food and Nutrition. Aug., p. 347.

Condon, William J.—Product Liability —1970. Apr., p. 144.

Consumer Class Suits—Righting the Wrongs to Consumers. Mar., p. 130.

Consumer Education and Information. Jan., p. 18 (Howard R. Dentz).

Consumer Education and Information. Sept., p. 443 (Mervyn Silverman).

Consumer Protection: Advertising—The FTC Response. Dec., p. 609.

Consumer Protection, Beef Producers View. Jan., p. 13.

Consumer Protection and Education

Consumer Class Suits—Righting the Wrongs to Consumers. Mar., p. 130.

Consumer Education and Information. Jan., p. 18 (Howard R. Dentz).

Consumer Education and Information. Sept., p. 443 (Mervyn Silverman).

Consumer Protection: Advertising—The FTC Response. Dec., p. 609.

Consumer Protection, Beef Producers View. Jan., p. 13.

Control of Television Advertising in Great Britain. Aug., p. 328.

Drug Abuse, Drug Culture, Drug Advertising. Oct., p. 482.

Drug Advertising and Drug Abuse —The Role of the FTC. Oct., p. 487.

Duty to Inform (The): The Responsibility to Comply. Mar., p. 102.

FDA-FTC Liaison: Teamwork That Pays Off. Sept., p. 439.

FDA's Consumer Programs. Jan., p. 22.

FDA's Product Safety Program. Feb., p. 70.

New Foods and Old Laws: Conflict or Accommodation? Dec., p. 644.

Poison Prevention Packaging Act (The). Sept., p. 447.

To Tell The Truth, The Whole Truth. . . . Apr., p. 173.

Control of Television Advertising in Great Britain. Aug., p. 328.

Cooper, Joseph D.—Self-Medication in the Light of Changing Patterns of Medical Care. Oct., p. 500.

Cooper, Theodore—Device Legislation. Apr., p. 165.

Corporate Counsel's Responsibility in the Age of Consumerism. Apr., p. 154.

Corrigan, James C.—The Poison Prevention Packaging Act. Sept., p. 447.

Court of Food and Drug Appeals (A). June, p. 279.

Creating a Legally Viable Food Product. Nov., p. 575.

Cultural and Social Foundations of Food Laws (The). July, p. 296.

D

Dentz, Howard R.—Consumer Education and Information. Jan., p. 18.

Device Legislation. Apr., p. 165.

Done, Alan K.—Future Prospects for New Proprietary Medications. Oct., p. 519.

Drug Abuse

Drug Abuse, Drug Culture, Drug Advertising. Oct., p. 482.

Drug Abuse: An Opportunity for Drug Lawyers. Mar., p. 111.

Drug Advertising and Drug Abuse—The Role of the FTC. Oct., p. 487.

Drug Abuse, Drug Culture, Drug Advertising. Oct., p. 482.

Drug Abuse: An Opportunity for Drug Lawyers. Mar., p. 111.

Drug Advertising and Drug Abuse—The Role of the FTC. Oct., p. 487.

Drug Listing Law Takes Shape. Sept., p. 435.

Drugs, Trademarks, and the FDA. May, p. 215.

Duty to Inform (The): The Responsibility to Comply. Mar., p. 102.

E

Efficacy Requirements of the Food, Drug, and Cosmetic Act (The). Dec., p. 683.

F

Fair Packaging and Labeling

Creating a Legally Viable Food Product. Nov., p. 575.

Formulation of Mandatory Food Standards (The). Sept., p. 376.

Making Products More Nutritious. Nov., p. 581.

Package as a Vehicle (The)—A Rocket Ship? Or a Hearse? Nov., p. 598.

Progress Report on the Fair Packaging and Labeling Act (A). Jan., p. 37.

Special Problems with Dietary Foods. Nov., p. 584.

Standardized Food and the Imitation Gambit. Nov., p. 578.

FDA-FTC Liaison: Teamwork That Pays Off. Sept., p. 439.

FDA's Consumer Programs. Jan., p. 22.

FDA's Implementation Procedures

After Panalba, Whither? Apr., p. 186.

Efficacy Requirements of the Food, Drug, and Cosmetic Act (The). Dec., p. 683.

XUM

Food and Drug Administration Regulations v. Drug Manufacturers' Hearing Rights: An Analysis. May, p. 224.

Industry Reaction to Prescription Drug Advertising Regulations and Their Enforcement. Oct., p. 534.

Litigation Resulting from NAS-NRC Review and FDA Demands for "New-Drug" Status. Oct., p. 464.

Private Remedies, Including Class Actions, Arising Out of Implementation of NAS-NRC Drug Efficacy Review. Dec., p. 667.

Variations on a Familiar Theme. Oct., p. 472.

FDA's Product Safety Program. Feb., p. 70.

Finkel, Marion J.—Progress Report on Clinical Guidelines. Feb., p. 78.

Flack, Duane E.—Consumer Protection, Beef Producers View. Jan., p. 13.

Food and Drug Administration

—And Where Has the Old Food and Drug Administration Gone? Oct., p. 539.

Drugs, Trademarks, and the FDA. May, p. 215.

FDA-FTC Liaison: Teamwork That Pays Off. Sept., p. 439.

FDA's Consumer Programs. Jan., p. 22.

FDA's Product Safety Program. Feb., p. 70.

Food and Drug Administration Regulations v. Drug Manufacturers' Hearing Rights: An Analysis. May, p. 224.

Microbiology in FDA—New Horizons. Jan., p. 28.

Report from FDA's Bureau of Foods and Pesticides. Aug., p. 358.

Food and Drug Administration Regulations v. Drug Manufacturers' Hearing Rights: An Analysis. May, p. 224.

Food, Drug, and Cosmetic Act

Analysis of the Application of the Salvaging Provision of the Food, Drug, and Cosmetic Act of 1938 (An). June, p. 240.

Formulation of Mandatory Food Standards (The). Sept., p. 376.

Legal Procedures and Responsibilities Under the Federal Food, Drug, and Cosmetic Act. Aug., p. 334.

New Animal Drug Amendments and Implementing Regulations —FDA's View on Their Effect on Sponsors. Feb., p. 56.

New Animal Drug Amendments and Implementing Regulations: Their Effect on Producers—Industry's View. Feb., p. 61.

Regulatory and Compliance Features. Feb., p. 67.

Food Standards

Food Standards and the White House Conference on Food and Nutrition. Aug., p. 347.

Formulation of Mandatory Food Standards (The). Sept., p. 376.

Legal Aspects of Technical Problems and Chemical Additives. Nov., p. 588.

Report from FDA's Bureau of Foods and Pesticides. Aug., p. 358.

Food Standards and the White House Conference on Food and Nutrition. Aug., p. 347.

Formulation of Mandatory Food Standards (The). Sept., p. 376.

Freer, Robert E., Jr.—FDA-FTC Liaison: Teamwork That Pays Off. Sept., p. 439 (R. Joel Slomoff, co-author).

Future Prospects for New Proprietary Medications. Oct., p. 519.

Future of Self-Medication—In Legal Perspective (The). Oct., p. 505.

G

Gérard, A.—The Cultural and Social Foundations of Food Laws. (E. J. Bigwood, co-author) July, p. 296.

Gesling, James O.—Regulatory and Compliance Features. Feb., p. 67.

Gomilla, John—A Progress Report on the Fair Packaging and Labeling Act. Jan., p. 37.

Goodrich, William W.—A Reply to Professor Hamilton's Comments and Recommendations for Procedural Reform. Dec., p. 639.

Gottlieb, Alvin L.—Legal Procedures and Responsibilities Under the Federal Food, Drug, and Cosmetic Act. Aug., p. 334.

Government-Industry Cooperation

—And Where Has the Old Food and Drug Administration Gone? Oct., p. 539.

Drug Listing Law Takes Shape. Sept., p. 435.

Future of Self-Medication—In Legal Perspective (The). Oct., p. 505.

Partners for Nutrition, Health and Safety. Feb., p. 76.

Regulating in the Public Interest. Nov., p. 593.

Grant, James D.

Challenge of Progress in Food (The). Aug., p. 365.

FDA's Consumer Programs. Jan., p. 22.

Grisanti, Eugene P.—Legal Aspects of Technical Problems and Chemical Additives. Nov., p. 588.

H

Hagan, Charles F.—The Efficacy Requirements of the Food, Drug, and Cosmetic Act. Dec., p. 683.

Hall, Richard L.—White House Conference Recommendations—Industry's Role. Feb., p. 48.

Hamilton, Robert W.—Rulemaking on a Record. Dec., p. 627.

Harmonization of Food Laws

Cultural and Social Foundations of Food Laws (The). July, p. 296.

Importance of Uniformity Among State Food and Drug Laws (The). Mar., p. 96.

International Aspects of Food and Drug Legislation. July, p. 303.

Hart, Samuel M.—FDA's Product Safety Program. Feb., p. 70.

Harvey, Richard D.—The Marketing Objective. Nov., p. 563.

Hearing Rights

After Panalba, Whither? Apr., p. 186.

Court of Food and Drug Appeals (A). June, p. 279.

Food and Drug Administration Regulations v. Drug Manufacturers' Hearing Rights: An Analysis. May, p. 224.

Litigation Resulting from NAS-NRC Review and FDA Demands for "New-Drug" Status. Oct., p. 464.

Reply to Professor Hamilton's Comments and Recommendations for Procedural Reform (A). Dec., p. 639.

Rulemaking on a Record. Dec., p. 627.

Hoffman, Joel E.—New Drugs, Old Drugs, and the NAS-NRC Efficacy Review. Mar., p. 118.

Hoge, James F.—The Future of Self-Medication—In Legal Perspective. Oct., p. 505.

Howard, Hartley W.—Making Products More Nutritious. Nov., p. 581.

I

Importance of Uniformity Among State Food and Drug Laws (The). Mar., p. 96.

Industry Reaction to Prescription Drug Advertising Regulations and Their Enforcement. Oct., p. 534.

International Aspects of Food and Drug Legislation. July, p. 303.

Investigational Clinical Studies. Jan., p. 4.

J

Jacobs, Thomas H.—An Analysis of the Application of the Salvaging Provision of the Food, Drug, and Cosmetic Act of 1938. June, p. 240.

Jones, Mary Gardiner—To Tell The Truth, The Whole Truth. . . . Apr., p. 173.

K

Kegan, Esther O.—Consumer Class Suits—Righting the Wrongs to Consumers. Mar., p. 130.

Kingma, Fred J.—New Animal Drug Amendments and Implementing Regulations—FDA's View on Their Effect on Sponsors. Feb., p. 56.

Kinslow, M. L.—The Duty to Inform: The Responsibility to Comply. Mar., p. 102.

Kirkpatrick, Miles W.—Regulating in the Public Interest. Nov., p. 593.

Kleinfeld, Vincent A.
Court of Food and Drug Appeals (A). June, p. 279.
New Drugs. May, p. 200.
Variations on a Familiar Theme. Oct., p. 472.

Klumpp, Theodore G.— —And Where Has the Old Food and Drug Administration Gone? Oct., p. 539.

Krantz, John C., Jr.—A Philosophical Approach to Self-Medication and Its Future. Oct., p. 513.

Kushen, Allan S.—New Animal Drug Amendments and Implementing Regulations: Their Effect on Producers —Industry's View. Feb., p. 61.

L

Lambert, Eugene I.
New Foods and Old Laws: Conflict or Accommodation? Dec., p. 644.
Standardized Food and the Imitation Gambit. Nov., p. 578.

Lawyers' Role
Corporate Counsel's Responsibility in the Age of Consumerism. Apr., p. 154.
Drug Abuse: An Opportunity for Drug Lawyers. Mar., p. 111.
To Tell The Truth, The Whole Truth. . . .Apr., p. 173.

Legal Aspects of Technical Problems and Chemical Additives. Nov., p. 588.

Legal Procedures and Responsibilities Under the Federal Food, Drug, and Cosmetic Act. Aug., p. 334.

Legislation
Device Legislation. Apr., p. 165.
Drug Listing Law Takes Shape. Sept., p. 435.
Legislative Overview, 1971—1972. Oct., p. 526.
Poison Prevention Packaging Act (The). Sept., p. 447.
Progress Report on the Fair Packaging and Labeling Act (A). Jan., p. 37.

Legislative Overview, 1971—1972. Oct., p. 526.

Lemker, John F., Jr.—Food and Drug Administration Regulations v. Drug Manufacturers' Hearing Rights: An Analysis. May, p. 224.

Lewis Carroll Might Have Written It. Oct., p. 458.

Licensing of Drugs

Drug Listing Law Takes Shape. Sept., p. 435.

Future of Self-Medication—In Legal Perspective (The). Oct., p. 505.

Legislative Overview, 1971—1972. Oct., p. 526.

Self-Medication in the Light of Changing Patterns of Medical Care. Oct., p. 500.

Variations on a Familiar Theme. Oct., p. 472.

Lisook, Alan B.—Investigational Clinical Studies. Jan., p. 4.

Litigation Resulting from NAS-NRC Review and FDA Demands for "New-Drug" Status. Oct., p. 464.

M

Making Products More Nutritious. Nov., p. 581.

Manoff, Richard K.—The New Products Challenge. Nov., p. 553.

Marketing Objective (The). Nov., p. 563.

Microbiology in FDA—New Horizons. Jan., p. 28.

Munsey, Rodney R.—Private Remedies, Including Class Actions, Arising Out of Implementation of NAS-NRC Drug Efficacy Review. Dec., p. 667.

N

NAS-NRC Efficacy Review

After Panalba, Whither? Apr., p. 186.

Efficacy Requirements of the Food, Drug, and Cosmetic Act (The). Dec., p. 683.

Lewis Carroll Might Have Written It. Oct., p. 458.

Litigation Resulting from NAS-NRC Review and FDA Demands for "New-Drug" Status. Oct., p. 464.

New Drugs, Old Drugs, and the NAS-NRC Efficacy Review. Mar., p. 118.

Private Remedies, Including Class Actions, Arising Out of Implementation of NAS-NRC Drug Efficacy Review. Dec., p. 667.

New Animal Drug Amendments

New Animal Drug Amendments and Implementing Regulations—FDA's View on Their Effect on Sponsors. Feb., p. 56.

New Animal Drug Amendments and Implementing Regulations: Their Effect on Producers—Industry's View. Feb., p. 61.

Regulatory and Compliance Features. Feb., p. 67.

New Animal Drug Amendments and Implementing Regulations—FDA's View on Their Effect on Sponsors. Feb., p. 56.

New Animal Drug Amendments and Implementing Regulations: Their Effect on Producers—Industry's View. Feb., p. 61.

New Drugs. May, p. 200.

New Drugs

Efficacy Requirements of the Food, Drug, and Cosmetic Act (The). Dec., p. 683.

Future of Self-Medication—In Legal Perspective (The). Oct., p. 505.

Litigation Resulting from NAS-NRC Review and FDA Demands for "New-Drug" Status. Oct., p. 464.

New Drugs. May, p. 200.

New Drugs, Old Drugs, and the NAS-NRC Efficacy Review. Mar., p. 118.

XUM

Research and Development of a New Drug. Jan., p. 9.

Variations on a Familiar Theme. Oct., p. 472.

New Drugs, Old Drugs, and the NAS-NRC Efficacy Review. Mar., p. 118.

New Food Products

Creating a Legally Viable Food Product. Nov., p. 575.

Legal Aspects of Technical Problems and Chemical Additives. Nov., p. 588.

Making Products More Nutritious. Nov., p. 581.

Marketing Objective (The). Nov., p. 563.

New Foods—Another Viewpoint. Dec., p. 651.

New Foods and Old Laws: Conflict or Accommodation? Dec., p. 644.

New Products Challenge (The). Nov., p. 553.

Package as a Vehicle (The)—A Rocket Ship? Or a Hearse? Nov., p. 598.

Special Problems with Dietary Foods. Nov., p. 584.

Standardized Food and the Imitation Gambit. Nov., p. 578.

Trouble with New Products (The). Nov., p. 569.

What Do We Mean by "New Products?" Nov., p. 558.

New Foods—Another Viewpoint. Dec., p. 651.

New Foods and Old Laws: Conflict or Accommodation? Dec., p. 644.

New Products Challenge (The). Nov., p. 553.

Nutritional Labeling

Creating a Legally Viable Food Product. Nov., p. 575.

Food Standards and the White House Conference on Food and Nutrition. Aug., p. 347.

Legal Aspects of Technical Problems and Chemical Additives. Nov., p. 588.

Making Products More Nutritious. Nov., p. 581.

New Foods—Another Viewpoint. Dec., p. 651.

New Foods and Old Laws: Conflict or Accommodation? Dec., p. 644.

Nutritional Labeling: An Analysis. Feb., p. 82.

Package as a Vehicle (The)—A Rocket Ship? Or a Hearse? Nov., p. 598.

Report from FDA's Bureau of Foods and Pesticides. Aug., p. 358.

Special Problems with Dietary Foods. Nov., p. 584.

Standardized Food and the Imitation Gambit. Nov., p. 578.

White House Conference Recommendations — Industry's Role. Feb., p. 48.

Nutritional Labeling: An Analysis. Feb., p. 82.

O

Olson, Joseph C., Jr.—Microbiology in FDA—New Horizons. Jan., p. 28.

Olsson, Philip C.—New Foods—Another Viewpoint. Dec., p. 651.

P

Package as a Vehicle (The)—A Rocket Ship? Or a Hearse? Nov., p. 598.

Partners for Nutrition, Health and Safety. Feb., p. 76.

Phelps, James R.—After Panalba, Whither? Apr., p. 186.

Philosophical Approach to Self-Medication and Its Future (A). Oct., p. 513.

Poison Prevention Packaging Act (The). Sept., p. 447.

Potpourri of Trademark and Labeling Regulations for Drug Products (A). May, p. 208.

Private Remedies, Including Class Actions, Arising Out of Implementation of NAS-NRC Drug Efficacy Review. Dec., p. 667.

Problems Relating to Enforcement of Food and Milk Laws and Regulations: Industry Viewpoint. July, p. 288.

Product Liability

Product Liability—1970. Apr., p. 144.

Product Liability—1970. Apr., p. 144.

Product Safety

FDA's Product Safety Program. Feb., p. 70.

Poison Prevention Packaging Act (The). Sept., p. 447.

Progress Report on Clinical Guidelines. Feb., p. 78.

Progress Report on the Fair Packaging and Labeling Act (A). Jan., p. 37.

R

Regulating in the Public Interest. Nov., p. 593.

Regulatory and Compliance Features. Feb., p. 67.

Reply to Professor Hamilton's Comments and Recommendations for Procedural Reform (A). Dec., p. 639.

Report from FDA's Bureau of Foods and Pesticides. Aug., p. 358.

Research and Development of a New Drug. Jan., p. 9.

Rulemaking on a Record. Dec., p. 627.

S

Self-Medication

Future Prospects for New Proprietary Medications. Oct., p. 519.

Future of Self-Medication—In Legal Perspective (The). Oct., p. 505.

Philosophical Approach to Self-Medication and Its Future (A). Oct., p. 513.

Self-Medication in the Light of Changing Patterns of Medical Care. Oct., p. 500.

Self-Medication in the Light of Changing Patterns of Medical Care. Oct., p. 500.

Seligman, David A.—Drugs, Trademarks, and the FDA. May, p. 215.

Silverman, Mervyn—Consumer Education and Information. Sept., p. 443.

Skinner, William J.

Drug Abuse: An Opportunity for Drug Lawyers. Mar., p. 111.

Drug Listing Law Takes Shape. Sept., p. 435.

Slomoff, R. Joel—FDA-FTC Liaison: Teamwork That Pays Off. Sept., p. 439 (Robert E. Freer, Jr., co-author).

Smoyer, Stanley C.—Industry Reaction to Prescription Drug Advertising Regulations and Their Enforcement. Oct., p. 534.

Some Aberrations in Administrative Law. June, p. 261.

Special Problems with Dietary Foods. Nov., p. 584.

Standardized Food and the Imitation Gambit. Nov., p. 578.

Stetler, C. Joseph—Legislative Overview, 1971—1972. Oct., p. 526.

T

Temko, Stanley L.—Litigation Resulting from NAS-NRC Review and FDA Demands for "New-Drug" Status. Oct., p. 464.

XUM

Thain, Gerald J.

Consumer Protection: Advertising —The FTC Response. Dec., p. 609.

Drug Advertising and Drug Abuse—The Role of the FTC. Oct., p. 487.

Thompson, Merrill S.

Package as a Vehicle (The)—A Rocket Ship? Or a Hearse? Nov., p. 598.

Problems Relating to Enforcement of Food and Milk Laws and Regulations: Industry Viewpoint. July, p. 288.

To Tell The Truth, The Whole Truth. . . . Apr., p. 173.

Trademark Regulations

Drugs, Trademarks, and the FDA. May, p. 215.

Package as a Vehicle (The)—A Rocket Ship? Or a Hearse? Nov., p. 598.

Potpourri of Trademark and Labeling Regulations for Drug Products (A). May, p. 208.

Trouble with New Products (The). Nov., p. 569.

V

Variations on a Familiar Theme. Oct., p. 472.

W

Wescoe, W. Clarke—Lewis Carroll Might Have Written It. Oct., p. 458.

What Do We Mean by "New Products?" Nov., p. 558.

What Is "Unfair Advertising"? Dec., p. 658.

White House Conference Recommendations—Industry's Role. Feb., p. 48.

White House Nutrition Conference

Food Standards and the White House Conference on Food and Nutrition. Aug., p. 347.

White House Conference Recommendations — Industry's Role. Feb., p. 48.

Wodicka, Virgil O.—Report from FDA's Bureau of Foods and Pesticides. Aug., p. 358.

Wood, Laurence I.—Partners for Nutrition, Health and Safety. Feb., p. 76.

Woodhouse, Peter—Control of Television Advertising in Great Britain. Aug., p. 328.

Z

Zimmerman, Julius G.—International Aspects of Food and Drug Legislation. July, p. 303.

XUM